Pharmacokinetic-pharmacodynamic analysis of conventional reversal of rocuronium-induced neuromuscular blockade by sugammadex under 2 years old children

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0010940

Enrollment

Registered

2025-08-26

Start date

2025-11-21

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : sugammadex 0.5, 1, 2 mg/kg single bolus intravenous injection neuromuscular blockade monitoring TOF 2 count

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: less than 2 years old

Exclusion criteria

Exclusion criteria: Pediatric patients whose parents or legal guardians refuse participation in the study Pediatric patients with a history of hypersensitivity to rocuronium or other drugs related to general anesthesia Pediatric patients with cardiovascular or genitourinary diseases Pediatric patients with severe renal impairment (creatinine clearance < 30 mL/min) or requiring dialysis Pediatric patients with severe hepatic impairment or coagulopathy Pediatric patients receiving neuromuscular blocking agents prior to surgery Pediatric patients taking medications that may affect the action of neuromuscular blocking agents (e.g., aminoglycosides, anticonvulsants, magnesium) Pediatric patients with a history of malignant hyperthermia Pediatric patients expected to have massive intraoperative bleeding Any other pediatric patients deemed unsuitable for the study by the investigator

Design outcomes

Primary

Measure	Time frame
hemodynamic instability	—

Secondary

Measure	Time frame
saturation monitor	—

Countries

Korea, Republic of

Contacts

Public ContactSang Hwan Ji

Seoul National University Hospital

taepoongshin@gmail.com+82-2-2072-3664

Outcome results